Medtronic's Afferaâ„¢ PFA Technologies Show Promising Results for Atrial Fibrillation Treatment
One-year clinical trial data for Medtronic's investigational Sphere-360â„¢ single-shot PFA catheter demonstrated 88% freedom from arrhythmia recurrence in paroxysmal atrial fibrillation patients, with no reported safety events in the optimized waveform subgroup.
Boston Scientific's FARAPULSE PFA System Shows Promising Results for Persistent Atrial Fibrillation Treatment
The second phase of Boston Scientific's ADVANTAGE AF trial demonstrated 73.4% freedom from atrial fibrillation, atrial flutter, and atrial tachycardia in patients with persistent AF, exceeding the performance goal of 40%.
Precision Neuroscience Secures FDA Clearance for Layer 7 Cortical Interface, Advancing BCI Technology
Precision Neuroscience has received FDA 510(k) clearance for its Layer 7 Cortical Interface, marking the first full regulatory approval for a next-generation wireless brain-computer interface technology.
Five Years Later: COVID-19's Lasting Impact on Oncology Care and Research
The COVID-19 pandemic has fundamentally transformed oncology care delivery, with telemedicine emerging as a permanent fixture that improves access while presenting challenges in patient assessment and reimbursement.
Mount Sinai's Dr. Vivek Reddy to Lead Orchestra BioMed's BACKBEAT Study as Executive Chairman
Orchestra BioMed has appointed renowned cardiac electrophysiologist Dr. Vivek Reddy as Executive Chairman of the BACKBEAT Study Steering Committee, strengthening leadership for their global pivotal trial.
Lurbinectedin Enhances Anti-Tumor Immunity in Small-Cell Lung Cancer via STING Pathway Activation
A Mount Sinai study elucidates that lurbinectedin, a second-line therapy for SCLC, enhances the immune response against tumors by activating the STING-IFN signaling pathway.
Major AI Healthcare Breakthroughs: From Surgical Training to Clinical Trial Matching
Johns Hopkins researchers successfully trained a robot to perform surgical tasks using surgical videos and ChatGPT's machine learning architecture, marking a significant advancement in AI-assisted surgery.
Tulisokibart Shows Promise in Treating Moderate to Severe Ulcerative Colitis
A Phase 2 trial of tulisokibart, an anti-TL1A monoclonal antibody, demonstrated superior efficacy compared to placebo in inducing clinical remission in patients with moderate to severe ulcerative colitis.
Librexia Program Aims for Inclusive Cardiovascular Clinical Trials
The Librexia program is a Phase 3 clinical trial focusing on novel treatments for blood clotting diseases, including acute coronary syndrome and atrial fibrillation.
AI and Behavioral Data to Predict Mental Health Treatment Outcomes in Young Adults
Mount Sinai and IBM Research are collaborating on the PREDiCTOR study to predict mental health treatment outcomes using AI and behavioral data.